Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States — Food and Drug Administration & AnBogen Therapeutics

6 shared events · Importance 3 · Last updated Sep 01, 2026

Importance
3
Shared Events
6
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
89
Regulatory
United States — Food and Drug Administration: The FDA provided written pre-IND responses raising no objections to Protagenic's Phase 1 program design and supporting packages, facilitating the company's path to IND submission. This action reflects the FDA's regulatory role in evaluating investigational drugs.
AnBogen Therapeutics: AnBogen Therapeutics is the developer of PT00114 and the recipient of FDA's pre-IND feedback. This positive regulatory milestone supports its clinical development plans and may enhance its market position, though the company still faces substantial financial and clinical risks.
Aug 20, 2026 · 6 articles
85
Regulatory
United States — Food and Drug Administration: The FDA approved Mimrylo and Besremi, expanding treatment options for rare blood cancers. Its decisions shape the regulatory landscape for these therapies.
AnBogen Therapeutics: Protagonist receives $275 million in payments and up to $875 million more plus royalties, boosting its financial independence and funding its pipeline. Its stock has nearly tripled over the past year.
Aug 28, 2026 · 6 articles
59
Business
United States — Food and Drug Administration: Granted Orphan Drug and Rare Pediatric Disease Designations for SYN-001; provided preliminary alignment on endpoints.
AnBogen Therapeutics: Founding investor and development partner; CEO Ivar Hakonarson becomes Chairman of Synaptiq.
Jul 23, 2026 · 6 articles
32
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration is currently reviewing the New Drug Application for rusfertide for the treatment of polycythemia vera.
AnBogen Therapeutics: AnBogen Therapeutics granted inducement awards to three new employees, consisting of stock options and restricted stock units, as a material inducement for their employment. This action aims to attract and retain talent, which is generally positive for the company's long-term prospects.
Jun 16, 2026 · 6 articles
32
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration is currently reviewing the New Drug Application for rusfertide.
AnBogen Therapeutics: AnBogen Therapeutics will participate in two investment bank conferences, providing an opportunity to present its pipeline and potentially attract investor interest.
May 28, 2026 · 6 articles
22
Business
United States — Food and Drug Administration: The FDA is reviewing the NDA for rusfertide. This event does not affect the FDA.
AnBogen Therapeutics: Protagonist granted inducement awards to new employees, reflecting ongoing talent acquisition. The company's pipeline includes ICOTYDE and rusfertide, with regulatory milestones ahead.
Aug 04, 2026 · 9 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States — Food and Drug Administration and AnBogen Therapeutics interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.